keyword
MENU ▼
Read by QxMD icon Read
search

PEGASUS

keyword
https://www.readbyqxmd.com/read/27910362/a-novel-cost-effective-multi-point-thomson-scattering-system-on-the-pegasus-toroidal-experiment-invited
#1
D J Schlossberg, G M Bodner, M W Bongard, R J Fonck, J A Reusch, C Rodriguez Sanchez
A novel, cost-effective, multi-point Thomson scattering system has been designed, implemented, and operated on the Pegasus Toroidal Experiment. Leveraging advances in Nd:YAG lasers, high-efficiency volume phase holographic transmission gratings, and increased quantum-efficiency Generation 3 image-intensified charge coupled device (ICCD) cameras, the system provides Thomson spectra at eight spatial locations for a single grating/camera pair. The on-board digitization of the ICCD camera enables easy modular expansion, evidenced by recent extension from 4 to 12 plasma/background spatial location pairs...
November 2016: Review of Scientific Instruments
https://www.readbyqxmd.com/read/27910356/control-and-automation-of-the-pegasus-multi-point-thomson-scattering-system
#2
G M Bodner, M W Bongard, R J Fonck, J A Reusch, C Rodriguez Sanchez, D J Schlossberg
A new control system for the Pegasus Thomson scattering diagnostic has recently been deployed to automate the laser operation, data collection process, and interface with the system-wide Pegasus control code. Automation has been extended to areas outside of data collection, such as manipulation of beamline cameras and remotely controlled turning mirror actuators to enable intra-shot beam alignment. Additionally, the system has been upgraded with a set of fast (∼1 ms) mechanical shutters to mitigate contamination from background light...
November 2016: Review of Scientific Instruments
https://www.readbyqxmd.com/read/27828825/pegasus-study-who-would-benefit-from-prolonged-dual-antiplatelet-therapy
#3
Leonardo De Luca
No abstract text is available yet for this article.
November 8, 2016: Journal of Cardiovascular Medicine
https://www.readbyqxmd.com/read/27819678/tet2-binds-the-androgen-receptor-and-loss-is-associated-with-prostate-cancer
#4
M L Nickerson, S Das, K M Im, S Turan, S I Berndt, H Li, H Lou, S A Brodie, J N Billaud, T Zhang, A J Bouk, D Butcher, Z Wang, L Sun, K Misner, W Tan, A Esnakula, D Esposito, W Y Huang, R N Hoover, M A Tucker, J R Keller, J Boland, K Brown, S K Anderson, L E Moore, W B Isaacs, S J Chanock, M Yeager, M Dean, T Andresson
Genetic alterations associated with prostate cancer (PCa) may be identified by sequencing metastatic tumour genomes to identify molecular markers at this lethal stage of disease. Previously, we characterized somatic alterations in metastatic tumours in the methylcytosine dioxygenase ten-eleven translocation 2 (TET2), which is altered in 5-15% of myeloid, kidney, colon and PCas. Genome-wide association studies previously identified non-coding risk variants associated with PCa and melanoma. We perform fine-mapping of PCa risk across TET2 using genotypes from the PEGASUS case-control cohort and identify six new risk variants in introns 1 and 2...
November 7, 2016: Oncogene
https://www.readbyqxmd.com/read/27766951/pgen-large-scale-genomic-variations-analysis-workflow-and-browser-in-soykb
#5
Yang Liu, Saad M Khan, Juexin Wang, Mats Rynge, Yuanxun Zhang, Shuai Zeng, Shiyuan Chen, Joao V Maldonado Dos Santos, Babu Valliyodan, Prasad P Calyam, Nirav Merchant, Henry T Nguyen, Dong Xu, Trupti Joshi
BACKGROUND: With the advances in next-generation sequencing (NGS) technology and significant reductions in sequencing costs, it is now possible to sequence large collections of germplasm in crops for detecting genome-scale genetic variations and to apply the knowledge towards improvements in traits. To efficiently facilitate large-scale NGS resequencing data analysis of genomic variations, we have developed "PGen", an integrated and optimized workflow using the Extreme Science and Engineering Discovery Environment (XSEDE) high-performance computing (HPC) virtual system, iPlant cloud data storage resources and Pegasus workflow management system (Pegasus-WMS)...
October 6, 2016: BMC Bioinformatics
https://www.readbyqxmd.com/read/27715344/pharmacokinetics-and-pharmacodynamics-of-ticagrelor-in-the-treatment-of-cardiac-ischemia
#6
Gian Marco Rosa, Daniele Bianco, Alberto Valbusa, Laura Massobrio, Francesco Chiarella, Claudio Brunelli
After acute coronary syndromes (ACS), the so-called dual antiplatelet therapy (DAPT), which usually consists of low-dose of aspirin in combination with a thienopyridine (clopidogrel, prasugrel) or with a cyclopentyltriazolopyrimidine (ticagrelor), reduces the risk of ischemic events. Ticagrelor, un particular, is an effective drug as it isn' a prodrug, doesn't require metabolic activation and demonstrates a rapid onset and faster offset of action. Areas covered: This article evaluates the pharmacokinetics, efficacy, safety and tolerability of ticagrelor during DAPT after ACS and its potential use beyond the canonical twelve months after PCI...
December 2016: Expert Opinion on Drug Metabolism & Toxicology
https://www.readbyqxmd.com/read/27635937/optimal-duration-of-dual-anti-platelet-therapy-after-percutaneous-coronary-intervention-2016-consensus-position-of-the-italian-society-of-cardiology
#7
Francesco Barillà, Francesco Pelliccia, Mauro Borzi, Paolo Camici, Livio Dei Cas, Matteo Di Biase, Ciro Indolfi, Giuseppe Mercuro, Vincenzo Montemurro, Luigi Padeletti, Pasquale Perrone Filardi, Carmine D Vizza, Francesco Romeo
Definition of the optimal duration of dual anti-platelet therapy (DAPT) is an important clinical issue, given the large number of patients having percutaneous coronary intervention (PCI), the costs and risks of pharmacologic therapy, the consequences of stent thrombosis, and the potential benefits of DAPT in preventing ischaemic outcomes beyond stent thrombosis. Nowadays, the rationale for a prolonged duration of DAPT should be not only the prevention of stent thrombosis, but also the prevention of ischaemic events unrelated to the coronary stenosis treated with index PCI...
January 2017: Journal of Cardiovascular Medicine
https://www.readbyqxmd.com/read/27576775/prevention-of-stroke-with-ticagrelor-in-patients-with-prior-myocardial-infarction-insights-from-pegasus-timi-54-prevention-of-cardiovascular-events-in-patients-with-prior-heart-attack-using-ticagrelor-compared-to-placebo-on-a-background-of-aspirin-thrombolysis
#8
Marc P Bonaca, Shinya Goto, Deepak L Bhatt, P Gabriel Steg, Robert F Storey, Marc Cohen, Erica Goodrich, Laura Mauri, Ton Oude Ophuis, Mikhail Ruda, Jindřich Špinar, Ki-Bae Seung, Dayi Hu, Anthony J Dalby, Eva Jensen, Peter Held, David A Morrow, Eugene Braunwald, Marc S Sabatine
BACKGROUND: In the PEGASUS-TIMI 54 trial (Prevention of Cardiovascular Events in Patients With Prior Heart Attack Using Ticagrelor Compared to Placebo on a Background of Aspirin-Thrombolysis in Myocardial Infarction 54), ticagrelor reduced the risk of major adverse cardiovascular events when added to low-dose aspirin in stable patients with prior myocardial infarction, resulting in the approval of ticagrelor 60 mg twice daily for long-term secondary prevention. We investigated the incidence of stroke, outcomes after stroke, and the efficacy of ticagrelor focusing on the approved 60 mg twice daily dose for reducing stroke in this population...
September 20, 2016: Circulation
https://www.readbyqxmd.com/read/27561167/do-randomized-clinical-trial-selection-criteria-reflect-levels-of-risk-as-observed-in-a-general-population-of-acute-myocardial-infarction-survivors-the-pegasus-trial-in-the-light-of-the-fast-mi-2005-registry
#9
Etienne Puymirat, François Schiele, Marianne Zeller, Laurent Jacquemin, Florence Leclercq, Xavier Marcaggi, Jean Ferrières, Tabassome Simon, Nicolas Danchin
BACKGROUND: Few clinical trials have focused on populations with a history of distant myocardial infarction (MI). The PEGASUS trial assessed the impact of dual antiplatelet therapy in such patients, selected by enrichment criteria of high cardiovascular risk. Whether the PEGASUS population reflects the risk of a broader post-MI population is questionable. We analyzed whether 4-year mortality of a routine-practice population would differ according to the inclusion and exclusion criteria used in PEGASUS...
November 15, 2016: International Journal of Cardiology
https://www.readbyqxmd.com/read/27532444/editorial-on-pegasus-timi-54
#10
EDITORIAL
Giulia Magnani, Marc P Bonaca, Marc S Sabatine
No abstract text is available yet for this article.
October 2015: European Heart Journal. Cardiovascular Pharmacotherapy
https://www.readbyqxmd.com/read/27499617/osg-gem-gene-expression-matrix-construction-using-the-open-science-grid
#11
William L Poehlman, Mats Rynge, Chris Branton, D Balamurugan, Frank A Feltus
High-throughput DNA sequencing technology has revolutionized the study of gene expression while introducing significant computational challenges for biologists. These computational challenges include access to sufficient computer hardware and functional data processing workflows. Both these challenges are addressed with our scalable, open-source Pegasus workflow for processing high-throughput DNA sequence datasets into a gene expression matrix (GEM) using computational resources available to U.S.-based researchers on the Open Science Grid (OSG)...
2016: Bioinformatics and Biology Insights
https://www.readbyqxmd.com/read/27489002/gene-and-network-analysis-of-common-variants-reveals-novel-associations-in-multiple-complex-diseases
#12
Priyanka Nakka, Benjamin J Raphael, Sohini Ramachandran
Genome-wide association (GWA) studies typically lack power to detect genotypes significantly associated with complex diseases, where different causal mutations of small effect may be present across cases. A common, tractable approach for identifying genomic elements associated with complex traits is to evaluate combinations of variants in known pathways or gene sets with shared biological function. Such gene-set analyses require the computation of gene-level P-values or gene scores; these gene scores are also useful when generating hypotheses for experimental validation...
October 2016: Genetics
https://www.readbyqxmd.com/read/27475614/erratum-multi-point-high-speed-passive-ion-velocity-distribution-diagnostic-on-the-pegasus-toroidal-experiment-rev-sci-instrum-83-10d516-2012
#13
M G Burke, R J Fonck, M W Bongard, D J Schlossberg, G R Winz
No abstract text is available yet for this article.
July 2016: Review of Scientific Instruments
https://www.readbyqxmd.com/read/27438319/long-term-tolerability-of-ticagrelor-for-the-secondary-prevention-of-major-adverse-cardiovascular-events-a-secondary-analysis-of-the-pegasus-timi-54-trial
#14
Marc P Bonaca, Deepak L Bhatt, Ton Oude Ophuis, P Gabriel Steg, Robert Storey, Marc Cohen, Julia Kuder, Kyungah Im, Giulia Magnani, Andrzej Budaj, Pierre Theroux, Christian Hamm, Jindrich Špinar, Robert G Kiss, Anthony J Dalby, Felix A Medina, Frederic Kontny, Philip E Aylward, Eva C Jensen, Peter Held, Eugene Braunwald, Marc S Sabatine
IMPORTANCE: In the PEGASUS-TIMI 54 trial, treatment with ticagrelor reduced the incidence of cardiovascular death, myocardial infarction, or stroke by 15% to 16% among stable patients compared with placebo. However, more patients prematurely discontinued treatment with ticagrelor than with placebo. OBJECTIVE: To investigate the reasons and timing of discontinuation of treatment with ticagrelor among stable patients prior myocardial infarction. DESIGN, SETTING, AND PARTICIPANTS: In the PEGASUS-TIMI 54 trial, 21 162 stable outpatients with prior myocardial infarction were randomly assigned to 90 mg of ticagrelor twice daily, 60 mg of ticagrelor twice daily, or placebo, with all of the patients receiving a low dose of aspirin...
July 1, 2016: JAMA Cardiology
https://www.readbyqxmd.com/read/27387972/timely-hemodynamic-resuscitation-and-outcomes-in-severe-pediatric-traumatic-brain-injury-preliminary-findings
#15
Nithya Kannan, Jin Wang, Richard B Mink, Mark S Wainwright, Jonathan I Groner, Michael J Bell, Christopher C Giza, Douglas F Zatzick, Richard G Ellenbogen, Linda Ng Boyle, Pamela H Mitchell, Frederick P Rivara, Ali Rowhani-Rahbar, Monica S Vavilala
OBJECTIVES: Early resuscitation may improve outcomes in pediatric traumatic brain injury (TBI). We examined the association between timely treatment of hypotension and hypoxia during early care (prehospital or emergency department locations) and discharge outcomes in children with severe TBI. METHODS: Hypotension was defined as systolic blood pressure less than 70 + 2 (age in years), and hypoxia was defined as PaO2 less than 60 mm Hg or oxygen saturation less than 90% in accordance with the 2003 Brain Trauma Foundation guidelines...
July 12, 2016: Pediatric Emergency Care
https://www.readbyqxmd.com/read/27334486/prolonged-dual-antiplatelet-therapy-in-stable-coronary-disease-comparative-observational-study-of-benefits-and-harms-in-unselected-versus-trial-populations
#16
A Timmis, E Rapsomaniki, S C Chung, M Pujades-Rodriguez, A Moayyeri, D Stogiannis, A D Shah, L Pasea, S Denaxas, C Emmas, H Hemingway
OBJECTIVE:  To estimate the potential magnitude in unselected patients of the benefits and harms of prolonged dual antiplatelet therapy after acute myocardial infarction seen in selected patients with high risk characteristics in trials. DESIGN:  Observational population based cohort study. SETTING:  PEGASUS-TIMI-54 trial population and CALIBER (ClinicAl research using LInked Bespoke studies and Electronic health Records). PARTICIPANTS:  7238 patients who survived a year or more after acute myocardial infarction...
June 22, 2016: BMJ: British Medical Journal
https://www.readbyqxmd.com/read/27258588/variation-in-seizure-prophylaxis-in-severe-pediatric-traumatic-brain-injury
#17
Paige J Ostahowski, Nithya Kannan, Mark S Wainwright, Qian Qiu, Richard B Mink, Jonathan I Groner, Michael J Bell, Christopher C Giza, Douglas F Zatzick, Richard G Ellenbogen, Linda Ng Boyle, Pamela H Mitchell, Monica S Vavilala
OBJECTIVE Posttraumatic seizure is a major complication following traumatic brain injury (TBI). The aim of this study was to determine the variation in seizure prophylaxis in select pediatric trauma centers. The authors hypothesized that there would be wide variation in seizure prophylaxis selection and use, within and between pediatric trauma centers. METHODS In this retrospective multicenter cohort study including 5 regional pediatric trauma centers affiliated with academic medical centers, the authors examined data from 236 children (age < 18 years) with severe TBI (admission Glasgow Coma Scale score ≤ 8, ICD-9 diagnosis codes of 800...
October 2016: Journal of Neurosurgery. Pediatrics
https://www.readbyqxmd.com/read/27192996/which-long-term-antiplatelet-regimen-for-patients-with-acute-coronary-syndromes
#18
REVIEW
Andrea Picchi, Marco Ferlini, Ugo Limbruno, Stefano De Servi
Dual antiplatelet therapy (DAPT ) is recommended up to 12 months in patients with acute coronary syndromes, but the risk of cardiovascular events in this group of subjects remains high, also in the long-term follow-up. The potential benefit of a prolonged period of DAPT has recently been assessed in three large-volume randomized clinical trials (PEGASUS, DAPT-MI, TRA2P-TIMI 50) but final results are quite difficult to interpret and clear indications for the clinical practice are so far lacking. A direct comparison of the three studies is challenging since relevant differences exist as to clinical features and risk profile of the study populations...
June 2016: Cardiovascular Drugs and Therapy
https://www.readbyqxmd.com/read/27160944/ticagrelor-for-the-treatment-of-atherosclerotic-disease-insights-from-the-parthenon-clinical-development-program
#19
Peter Held, Anders Himmelmann, Marc Ditmarsch
Ticagrelor (P2Y12 receptor antagonist) is presently indicated for preventing atherothrombotic events in patients with acute coronary syndrome and patients with a history of myocardial infarction. The PARTHENON clinical development program comprises five randomized, controlled, cardiovascular, indication-seeking outcome studies, aiming to evaluate ticagrelor across the spectrum of patients with atherothrombotic disease. Results of two large-scale trials support a benefit for ticagrelor in patients with acute coronary syndrome (PLATO; ClinicalTrials...
July 2016: Future Cardiology
https://www.readbyqxmd.com/read/27128533/missed-bleeding-events-after-ticagrelor-in-pegasus-trial-massive-non-compliance-information-censoring-or-both
#20
EDITORIAL
Victor Serebruany, Ales Tomek
PEGASUS trial reported reduction of composite primary endpoint after conventional 180mg/daily ticagrelor (CT), and lower 120mg/daily dose ticagrelor (LT) at expense of extra bleeding. Following approval of CT and LT for long-term secondary prevention indication, recent FDA review verified some bleeding outcomes in PEGASUS. To compare the risks after CT and LT against placebo by seven TIMI scale variables, and 9 bleeding categories considered as serious adverse events (SAE) in light of PEGASUS drug discontinuation rates (DDR)...
July 15, 2016: International Journal of Cardiology
keyword
keyword
45375
1
2
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read
×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"